Ocera Therapeutics, Inc. and Tranzyme, Inc. have completed their merger. The combined company, called Ocera Therapeutics, Inc., will operate under the leadership of Linda S. Grais, MD, president and chief executive officer. The board of directors consists of representatives from both Ocera and Tranzyme.   Following the closing of the merger, certain Ocera investors, including Domain Associates, Thomas McNerney & Partners, Sofinnova Ventures, InterWest Partners, Greenspring Associates, Ageche...